Newbridge Financial Services Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Newbridge Financial Services Group’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30	Closed	-$382	–	1223
2023 Q3	$382	Hold	30	–	–	﹤0.01%	1217
2023 Q2	$542	Hold	30	–	–	﹤0.01%	1257
2023 Q1	$516	Hold	30	–	–	﹤0.01%	1319
2022 Q4	$666	Hold	30	–	–	﹤0.01%	1340
2022 Q3	$0	Hold	30	–	–	﹤0.01%	1412
2022 Q2	$0	Hold	30	–	–	﹤0.01%	1406
2022 Q1	$0	Hold	30	–	–	﹤0.01%	1475
2021 Q4	$1K	Hold	30	–	–	﹤0.01%	1320
2021 Q3	$1K	Hold	30	–	–	﹤0.01%	1253
2021 Q2	$1K	Hold	30	–	–	﹤0.01%	1350
2021 Q1	$1K	Buy	+30	New	+$1.33K	﹤0.01%	1267

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Newbridge Financial Services Group's FDMT Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of 4D Molecular Therapeutics (FDMT) in Q4 2023, closing a stake of 30 shares — an estimated $382 sold.

Newbridge Financial Services Group first reported a position in FDMT in Q1 2021 and held it in 11 quarters. The position peaked at $1K in Q4 2021. 111 funds tracked by Wall St. Rank hold FDMT as of Q4 2023.

Newbridge Financial Services Group reported no remaining 4D Molecular Therapeutics position as of Q4 2023 after selling out during the quarter.
Newbridge Financial Services Group sold 30 4D Molecular Therapeutics shares in Q4 2023, an estimated $382.
Newbridge Financial Services Group first reported a position in 4D Molecular Therapeutics in Q1 2021 and held it in 11 quarters.
Newbridge Financial Services Group's 4D Molecular Therapeutics position peaked at $1K in Q4 2021.
111 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.